Criterium’s Oncology Consortia Makes Waves at ASCO 2024 Annual Conference

The Academic GI Cancer Consortium (AGICC) is represented by Key Opinion Leaders (KOLs) and Top Investigators from prestigious institutions in the USA. They are involved in designing and rapidly completing clinical trials in gastrointestinal (GI) cancers, aiming to improve patient outcomes through cutting-edge research. Two of our top AGICC PIs who attended the ASCO 2024 Annual Conference, shared valuable insights and progress from their innovative research model and clinical trials. We take great pleasure in congratulating Dr. Deirdre Cohen and Dr. Robert Lentz for the success of their Poster Presentations at the conference:

Deidre CohenDr. Deirdre J. Cohen presented a poster at the 2024 ASCO Annual Meeting on perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma (PDAC). The study, conducted by the Academic Gastrointestinal Cancer Consortium (AGICC), evaluated a perioperative strategy involving combination chemotherapy and preoperative stereotactic radiation therapy (SBRT) to improve the R0 resection rate in PDAC patients. The goal was to achieve complete surgical resection with no visible or microscopic disease left behind. The optimal role and type of neoadjuvant therapy (NAT) for improving R0 resection rate and overall survival (OS) in PDAC patients remain controversial1. Additionally, another study explored racial disparities and tumor characteristics of CA19-9 producer and non-producer patients with advanced PDAC, providing implications for survival and personalized treatment strategies1. For more details, you can explore the abstracts and presentations from the ASCO Annual Meeting. 

Robert LentzDr. Robert William Lentz presented a poster at the 2024 ASCO Annual Meeting on a phase 2 study involving evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC). Single-agent anti-PD-1/PD-L1 drugs are ineffective in MSS CRC, and this study aimed to explore a combination therapy approach. The safety-evaluable population included 16 patients, and the most common treatment-emergent adverse events were headache, fatigue, anemia, diarrhea, and dyspnea. The study investigated the recommended dose of E with CP and the objective response rate (ORR) by RECIST v1.11.

For more details, you can explore the abstracts and presentations from the ASCO Annual Meeting. 

Recommended Posts